Title: Study Suggests Lower Risk of Adverse Events with mRNA-1273 COVID-19 Vaccine Compared to BioNTech and Pfizer Vaccine
In a recent study published in JAMA Network Open, researchers have found that the mRNA-1273 (Moderna) COVID-19 vaccine may carry a lower risk of adverse events compared to its counterpart, the BioNTech and Pfizer vaccine. The study aimed to explore and compare the adverse events associated with both mRNA vaccines, focusing on different variables such as frailty levels and previous adverse events.
To carry out the study, researchers utilized a database of community pharmacies where Medicare claims were analyzed. This represented a significant portion, over 50%, of the US Medicare population. Individuals aged 66 years or older who had received either mRNA vaccine as their first COVID-19 vaccine were included in the study.
The investigation specifically examined 12 serious adverse events identified by the FDA as potentially connected to mRNA vaccines. Additionally, the researchers measured frailty using the claims-based frailty index and considered the risk of COVID-19 as a secondary outcome.
The study’s findings showed that although the risk of all outcomes was generally low for both vaccine groups, the mRNA-1273 vaccine was associated with a lower risk of certain adverse events. Notably, the risk of pulmonary embolism was reduced in those who received the mRNA-1273 vaccine. Furthermore, the mRNA-1273 vaccine demonstrated a lower risk of COVID-19 diagnosis, although this was influenced by the level of frailty.
It is important to note that the study did not determine whether the observed differences in adverse events were solely due to the safety or efficacy of the vaccines. The investigators have stressed the need for further research to establish the disparities in vaccine safety and efficacy for COVID-19 vaccines. Additionally, they aim to explore how the performance of these vaccines may be affected by immunocompromised conditions.
As COVID-19 vaccination efforts continue to play a crucial role in curbing the spread of the virus, studies like these provide valuable insights into the safety and effectiveness of different vaccine options. The findings of this particular study highlight the potential benefits of the mRNA-1273 vaccine in reducing the risk of certain adverse events. However, further investigation is necessary to fully understand the nuances of these differences and their implications for different population groups.
Overall, this study contributes to the ongoing efforts to improve our understanding of COVID-19 vaccines, their safety profiles, and their potential impact on diverse individuals.
“Prone to fits of apathy. Devoted music geek. Troublemaker. Typical analyst. Alcohol practitioner. Food junkie. Passionate tv fan. Web expert.”